Joe Rogan Peptides Episodes: 12 In-Depth Discussions

Looking for Joe Rogan podcast episodes that actually spend time on peptides? The most useful conversations go beyond a passing mention and explore specific compounds, personal experiences, scientific questions or the debate over access.

This guide brings together 12 JRE episodes with meaningful peptide discussions, ordered from oldest to newest. They cover BPC-157, TB-500, growth-hormone-related peptides and the growing conversation around compounding and regulation.

We selected episodes with a distinct exchange about the subject and excluded standalone jokes, casual supplement lists and Ozempic-only conversations. This is a curated listening guide, rather than every peptide reference in the podcast’s history.

A note on interpretation: An episode can document what Rogan or a guest said without proving that a treatment works. This independent guide distinguishes personal accounts, proposed explanations and policy arguments; it is not Joe Rogan’s official website or a treatment protocol.

Joe Rogan Peptides Episodes at a Glance

Choose an episode below to jump to its summary. Passage times are approximate transcript locations; advertisements and different audio or video editions can shift the timing.

1. JRE #1069: Ben Greenfield (January 29, 2018)

Ben Greenfield’s January 2018 appearance is an early starting point for following the recovery-peptide conversation on JRE. During a broader discussion of injuries and regenerative treatments, he brings up BPC-157 and TB-500.

Greenfield connects the compounds with his own attempts to address physical problems and describes their proposed roles in recovery. Rogan asks questions as the conversation moves between peptides, stem cells and other interventions.

The historical value is that these compounds were already being discussed explicitly on the podcast years before the later Huberman episodes. It also shows how closely the early peptide conversation overlapped with broader experimentation in performance and longevity.

Watch the exchange below:

2. JRE #1235: Ben Greenfield (January 30, 2019)

Greenfield’s return in January 2019 adds something especially relevant to readers asking what Joe Rogan has personally taken. During a conversation about his shoulder, Rogan says he used BPC-157.

The surrounding discussion includes stem-cell treatment and changes in the condition of the shoulder. That context matters: the account does not isolate BPC-157 as the reason for the improvement.

Greenfield also discusses TB-500, epitalon and melanotan as the conversation expands from injury recovery into longevity and tanning. Those additional compounds should be attributed to the discussion, rather than automatically added to a list of peptides Rogan uses.

Watch the exchange below:

Find the discussion: Read the JRE #1235 transcript, starting around 34:31.

3. JRE #1683: Andrew Huberman (July 14, 2021)

Andrew Huberman’s first JRE appearance contains a substantial peptide segment late in the conversation. Rogan and Huberman move from melanotan and pigmentation into BPC-157, recovery experiences and compounds connected with growth-hormone release.

Tesamorelin and ipamorelin come up as they discuss stimulating hormone production rather than simply administering a hormone. The range of examples makes this a useful introduction to why the word “peptides” can cover very different topics.

Rogan contributes personal recovery anecdotes, while Huberman discusses biological explanations and proposed effects. Listening to the full exchange gives more context than a short clip built around a dramatic healing claim.

Watch the exchange below:

4. JRE #1744: Derek, More Plates More Dates (December 3, 2021)

Derek’s December 2021 appearance is the strongest fit here for readers interested in the growth-hormone side of the peptide conversation. The relevant segment includes sermorelin, CJC-1295 and ipamorelin.

Rogan asks about compounds he recognizes, and Derek compares approaches to stimulating growth-hormone release. Their discussion sits within a much longer conversation about bodybuilding, hormones, performance enhancement and drug testing.

The value of this episode is its specificity: the speakers move beyond treating every peptide as the same kind of product. They discuss different compounds and the reasoning behind combining particular approaches.

Expect more terminology than in the Greenfield recovery stories. This is a useful follow-up to #1683 for understanding the conversation around hormone-related peptides.

Watch the exchange below:

5. JRE #2060: Gary Brecka (November 9, 2023)

Gary Brecka’s appearance connects peptides with a broader discussion of health, body composition and Dana White’s lifestyle changes. In describing that program, Brecka names sermorelin and ipamorelin and explains the role he believes they played.

BPC-157 and objections to peptide restrictions also appear elsewhere in the episode. The conversation therefore covers both individual compounds and the question of who should have access to them.

What makes this episode distinctive is the surrounding package of interventions: diet, lifestyle changes, monitoring and other treatments are discussed alongside peptides. A transformation described in that setting cannot be attributed to one ingredient alone.

Watch this entry for the details of Brecka’s account and how he presents peptides within a larger program. The timestamp below points to the growth-hormone-related portion, rather than every peptide reference in the episode.

Watch the exchange below:

6. JRE #2079: Brigham Buhler (December 27, 2023)

Peptides are a central topic from the opening of Brigham Buhler’s December 2023 appearance. He and Rogan discuss restrictions, compounding pharmacies, pharmaceutical incentives and their objections to the direction of regulation.

BPC-157 appears within a larger argument about access to treatments that patients and clinicians want to use. Buhler also argues that restricting legitimate access can push demand toward less accountable sellers.

This episode is useful for understanding the position advanced by peptide-access advocates. It contains forceful claims about safety and commercial motives, which should be read as the speakers’ arguments rather than conclusions established by the interview.

Its contribution to this timeline is the shift from individual recovery stories toward policy and distribution. It sets up the later Buhler and Kennedy conversations, where similar concerns return in a different political setting.

Watch the exchange below:

7. JRE #2376: Brigham Buhler (September 9, 2025)

Buhler’s September 2025 return starts with weight-loss drugs but broadens into a discussion of peptide access, compounding and product quality. GHK/copper peptides and BPC-157 also enter the conversation.

The speakers connect the commercial success of GLP-1 medicines with wider questions about pharmaceutical companies and compounding pharmacies. Rogan raises concerns about products bought online that may not contain what the customer expects.

This earns a place in the guide because the discussion extends beyond an Ozempic reference. It examines the supply side of the peptide market and the relationship between demand, regulation and confidence in a product’s contents.

Read it alongside #2079 to follow the development of Buhler’s argument. His business involvement in this area is relevant context when evaluating his perspective on access and competition.

Watch the exchange below:

8. JRE #2421: Derek, More Plates More Dates (December 2, 2025)

Derek’s December 2025 appearance brings the discussion back to a concrete recovery situation. Around the one-hour mark, he and Rogan discuss an Achilles problem, rehabilitation and the pairing of BPC-157 with TB-500.

The exchange includes personal observations about treatment and improvement, along with opinions about how the compounds are used. Those details explain why this combination attracts attention in athletic and bodybuilding conversations.

Melanotan appears later, giving the episode an additional peptide-related thread. The recovery segment is the stronger starting point for readers following BPC-157 and the combination commonly nicknamed the Wolverine stack.

Pair this with Derek’s 2021 appearance to see the contrast in subject matter: #1744 emphasizes growth-hormone-related compounds, while #2421 includes a specific rehabilitation account.

Watch the exchange below:

9. JRE #2450: Tommy Wood (February 6, 2026)

Tommy Wood’s appearance adds an important disagreement to this list. When peptides come up in the context of athletes and recovery, he presses for high-quality human evidence rather than accepting enthusiasm or biological plausibility as sufficient.

Rogan raises BPC-157 and sleep-related peptides, including a discussion of delta sleep-inducing peptide. Wood asks what the studies actually demonstrate and raises questions about product contents and the practical uncertainties surrounding use.

That back-and-forth makes this one of the most useful conversations for evaluating the claims repeated elsewhere on JRE. The discussion exposes the gap between reporting an experience, proposing an explanation and demonstrating a reliable treatment effect.

Watch the exchange below:

Find the discussion: Read the JRE #2450 transcript, starting around 1:05:05.

10. JRE #2461: Robert F. Kennedy Jr. (February 27, 2026)

Rogan directly asks Kennedy where things stand on peptide regulation. Kennedy responds with an account of compounding restrictions, demand for peptides and the growth of sellers marketing products for research or animal use.

He also describes personal experience with peptides and discusses changes he hopes to see. The exchange focuses on access and the difficulty of knowing what an unregulated product contains.

Although the peptide segment is shorter than some of the dedicated Buhler discussions, it is a focused exchange with clear policy significance. It is useful for understanding what Kennedy said publicly at that point in time.

Keep the date attached to any quotation from this episode. A proposed change, an expected announcement and a completed agency action are different things, so the interview should not be used by itself to establish today’s legal status.

Watch the exchange below:

11. JRE #2469: Brigham Buhler (March 18, 2026)

Buhler’s March 2026 appearance revisits peptide regulation shortly after the Kennedy interview. The discussion covers his account of conversations with officials, the position of compounding pharmacies and the consequences he associates with restrictions.

Rogan and Buhler also discuss gray-market products, pharmaceutical competition and the challenge of creating a route for patients to obtain consistent products. BPC-157 and GLP-1 drugs both appear within that wider argument.

This is the most useful of the selected Buhler episodes for following the 2026 policy conversation in detail. It provides more room for his reasoning than the shorter exchange with Kennedy.

The two episodes work best together: #2461 records Kennedy’s stated position, while #2469 develops Buhler’s perspective on the same access questions.

Watch the exchange below:

12. JRE #2553: Andrew Huberman (September 14, 2026)

Huberman’s September 2026 appearance is the newest episode in this selection. The peptide discussion links BPC-157 with a broader set of interests, including sleep, reproductive signaling and metabolic treatments.

Pinealon and kisspeptin come up alongside familiar recovery compounds, while GLP-1 medicines and retatrutide feature in the wider conversation. Huberman and Rogan also discuss why patients, physicians and online communities are interested in these substances.

The episode shows how far the subject has expanded since the early Greenfield appearances. Recovery remains a recurring theme, but it now sits beside discussions of other biological systems, commercial development and access to information.

Watch the exchange below:

Which Episode Should You Start With?

For an introduction covering several peptide categories, start with Andrew Huberman in #1683. For Rogan’s own early BPC-157 account, go to Ben Greenfield in #1235.

If your main interest is evaluating the evidence, prioritize Tommy Wood in #2450. For the access debate, listen to Kennedy in #2461 and then Buhler in #2469.

For a compound-by-compound overview, see our guide to the peptides Joe Rogan has discussed.

How the Podcast Claims Compare With Research

The distinction raised in the Wood episode also appears in the published literature. A 2025 systematic review of BPC-157 in orthopaedic sports medicine, covering literature through June 2024, included 35 preclinical studies and one clinical study.

That review helps explain why encouraging laboratory findings and recovery stories should not be treated as equivalent to strong human evidence. Its findings describe the literature covered by that review, not every study that may have appeared since.

There is also a separate regulatory distinction: the FDA states that compounded drugs are not FDA-approved. A discussion about allowing a pharmacy to compound a substance therefore should not be described as approval of that substance as a finished medicine.

Frequently Asked Questions

What was the first Joe Rogan episode about BPC-157?

The earliest explicit BPC-157 and TB-500 conversation located in our research was #1069 with Ben Greenfield, released January 29, 2018. Earlier episodes contain broader peptide references, so this should not be confused with the first time the word “peptide” appeared on JRE.

Has Joe Rogan said he used BPC-157?

Yes. In #1235 with Ben Greenfield, Rogan reports using BPC-157 during a discussion of his shoulder; that is a historical account and does not establish his current regimen.

Does discussing a peptide mean Rogan takes it?

No. A guest can describe a compound, explain an experiment or discuss someone else’s experience without Rogan saying he uses it.

Why are some popular peptide clips missing?

This page prioritizes 12 substantive conversations with different contributions to the topic. It is not an exhaustive list, and the absence of an episode does not mean peptides were never discussed there.

References & Sources

Each episode summary links to the transcript used to locate its discussion. These are third-party transcripts; consult the original recording for exact wording, since transcription errors can affect compound names and timestamps.

• Vasireddi and colleagues. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025.
• U.S. Food and Drug Administration. Understanding the Risks of Compounded Drugs.